126059-07-2

Upstream product

• 126059-06-1 3-butyryl-6-benzoyloxy-8-methoxy-4(1H)-quinolone 
• 126059-05-0 ethyl 2-butyryl-3-<<4-(benzoyloxy)-2-methoxyphenyl>amino>acrylate 
• 126059-04-9 ethyl 2-butyryl-3-<(4-hydroxy-2-methoxyphenyl)amino>acrylate 
• 61638-01-5 4-Amino-3-methoxyphenol 
• 150-19-6 O-methylresorcine 
• 125500-84-7 ethyl 2-(ethoxymethylene)-3-oxohexanoate 
• 3249-68-1 ethyl butyroyl acetate 

Relevant academic research and scientific papers

Reversible inhibitors of the gastric (H+/K+)-ATPase. 4. Identification of an inhibitor with an intermediate duration of action

3-Acyl-4-(arylamino)quinolines were previously identified as gastric (H+/K+)-ATPase inhibitors, and clinical efficacy has been demonstrated for compound 3 (SK and F 96067). In the present study the further structure- activity relatio

Substituted 4-aminoquinoline derivatives as gastric secretion inhibitors

Substituted 4-aminoquinazoline derivatives of the formula: STR1 wherein R1 is hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy C1-6 alkyl, C3-6 cycloalkyl, C3-6 cycloalkyl C1-6 alkyl, phenyl C1-6 alkyl, the phenyl group being optionally substituted; R2 is hydrogen, C1-6 alkyl, C1-6 alkoxy, amino, C1-6 alkylthio, halogen, cyano, hydroxy, C1-6 alkanoyl or trifuromethyl; m is 1 to 3; R3 is hydrogen, C1-6 alkyl, phenyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 alkanoyl, amino, C1-6 alkylamino, ci-C1-6 alkylamino, halogen, trifluoromethyl or cyano; n is 1 or 2; and R4 is hydrogen; or a salt thereof are useful as inhibitors of gastric acid secretion.